Clinical Trial Update: Pacritinib in Patients With Endothelial Growth Factor (EGFR) Mutant Non-small Cell Lung Cancer (NSCLC) After EGFR Tyrosine Kinase Inhibitor (TKI) [Phase 1]

View source ↗

Summary

Phase 1 trial of pacritinib in EGFR-mutant non-small cell lung cancer after EGFR-TKI has been terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Pacritinib (pacritinib)

Snippet

Sponsor: Washington University School of Medicine | Conditions: Non-Small Cell Lung Cancer, Nonsmall Cell Lung Cancer | Phase 1 | Status: TERMINATED